CDA-AMC
@CDA_AMC
Followers
19K
Following
12K
Media
8K
Statuses
27K
Canada’s Drug Agency – L'Agence des médicaments du Canada. Tweets, RTs, and Likes ≠ Endorsements
Ottawa, ON
Joined December 2011
Moving forward, we are stepping away from X to focus on connecting with you through other platforms. Thank you for your support and engagement on this platform. You can find us on: LinkedIn: https://t.co/q0L9ITQT1r Facebook: https://t.co/miffANUDwA Instagram:
0
0
2
À l’avenir, nous délaisserons X pour communiquer avec vous par le biais d’autres plateformes. Nous vous remercions de votre soutien et de votre engagement ici. Retrouvons-nous sur : LinkedIn : https://t.co/q0L9ITQT1r Facebook : https://t.co/miffANUDwA Instagram :
0
1
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on pembrolizumab (#Keytruda) for cervical cancer. Deadline is April 7, 2025: https://t.co/fcwpUZrCGe
#HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des observations sur le pembrolizumab
0
0
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on acalabrutinib (#Calquence) for mantle cell lymphoma (#MCL). Deadline is April 7, 2025: https://t.co/Ild3PKP3dt
#HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des observations sur
0
0
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on nivolumab and ipilimumab (#Opdivo and #Yervoy) for unresectable or metastatic MSI-H or dMMR colorectal cancer. Deadline is April 7, 2025: https://t.co/3pt5W1LScg
#HTA --- ⚠️Appel d’observations, patients et
0
0
0
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on talazoparib (#Talzenna) for metastatic castration-resistant prostate cancer. Deadline is April 7, 2025: https://t.co/QWn7mAZRoN
#HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des
0
0
0
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on risankizumab (#Skyrizi) for ulcerative colitis. Deadline is April 11, 2025: https://t.co/Bjyon3hl6H
#HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur le risankizumab
0
1
0
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on pembrolizumab (#Keytruda) for head and neck squamous cell carcinoma. Deadline is March 31, 2025: https://t.co/9tIbU5Hlmo
#HTA --- ⚠️Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des
0
0
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on risperidone (#Okedi) for schizophrenia in adults. Deadline is March 31, 2025: https://t.co/lJlIOnHX23
#HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur la
0
0
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on glofitamab (#Columvi) for relapsed or refractory diffuse large B-cell lymphoma. Deadline is March 24, 2025: https://t.co/o3e5CYYICa
#HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons des
0
0
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on asciminib (#Scemblix) for Philadelphia chromosome-positive chronic myeloid leukemia. Deadline is March 24, 2025: https://t.co/MK0qeCJdoZ
#HTA --- Appel d’observations, patients et cliniciens ⚠️ Nous sollicitons
1
0
1
⚠️Call for Patient and Clinician Input⚠️ We are requesting input on pegunigalsidase alfa for Fabry disease. Deadline is March 31, 2025: https://t.co/s844D6u9CC
#HTA --- ⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur le pégunigalsidase alfa
0
0
1
We've joined @icer_review and @NICEComms to select the first research topic for the Health Economics Methods Advisory group: an assessment of the benefits of treatment that are appropriate to consider in #HTA decision-making. 👉 https://t.co/ME3JvBnwhh
0
3
2
Le Groupe consultatif HEMA choisit son premier sujet de recherche : Évaluer les bienfaits à prendre en considération dans la prise de décisions en ETS. 👉 https://t.co/cB0ceKTrLD
0
0
0